State of the art while managing diabetes in older adults: eight case studies with focus on sglt-2 inhibitors and metformin

Çatıkkaş N. M., Bahat-Öztürk G., Karan M. A., Petrovic M.

2021 ESPEN Virtual, 9 - 14 September 2021, vol.46, pp.743, (Summary Text)

  • Publication Type: Conference Paper / Summary Text
  • Volume: 46
  • Doi Number: 10.1016/j.clnesp.2021.09.562
  • Page Numbers: pp.743
  • Istanbul University Affiliated: Yes

Abstract

Rationale: Sodium-glucose co-transporter-2 (SGLT-2) inhibitors have been recently introduced for type 2 diabetes treatment with significant cardiovascular, renal benefits. Yet, they have frequently been refrained in older adults. Metformin is regarded the firstline diabetes therapy in all ages; still it is associated with weight loss and frailty in older adults. We aimed to outline our experience with three oldest-old patients with high cardiovascular risk managed with SGLT-2 inhibitors, and five patients with anorexia/weight loss managed by metformin cessation.